Tumour Marker Panel (CEA, AFP, CA 19-9, CA 125, CA 15-3)
Last reviewed 25 August 2026 · Evidence-graded review — see Methodology
The most misleading line on a Singapore executive health invoice. These proteins are genuinely useful for monitoring a cancer that has already been diagnosed — tracking whether treatment is working. Used as a screen in a healthy person they produce far more false alarms than cancers, and a false alarm here means scans, biopsies and months of fear.
The idea has been tested most rigorously with CA 125. Menon U, Gentry-Maharaj A, et al. “Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.” Lancet 2021;397:2182–2193 randomised 202,638 postmenopausal women to annual CA 125-based screening, annual ultrasound, or no screening. The screening arm found more early-stage disease and still showed no significant reduction in ovarian cancer mortality. No major guideline body recommends any marker on this panel for screening asymptomatic adults.
Menon U, et al. Lancet. 2021. PubMed: PMID 33991479
Singapore guidance
Not recommended for screening
Singapore’s national screening committee lists tumour markers as not recommended for screening — separately under breast, colorectal and lung cancer.
Source: Screening Test Review Committee report 2026, Volume 1 (Academy of Medicine Singapore and Ministry of Health, February 2026), Tables 1A(i), 1C(i), 1D(i). The full national list · How this is used.
What you would actually pay
- Healthier SG
- Not subsidised
- MediSave
- Not among the screenings named for outpatient claims
Source: Healthier SG Screening (HealthHub) and MediSave outpatient care (Ministry of Health). Absence from either list is not a statement that the test is discouraged — only that no subsidy or claim applies. Gross prices compared.
What it costs when it is wrong
- Basis
- Follow-up cascade
- Severity
- Material
The committee advises against screening with this test in people without symptoms, citing the risk of follow-up tests after a positive result.
This follows from the committee’s criteria for the test’s category, not from a false-positive study of this test.
Screening harm is not only a laboratory question: the committee’s own criteria advise against a test when “the screening test, or follow-up tests arising from a positive screen, are associated with significant medical risks”. Sources on overdiagnosis → · How this is graded.
FAQ
Is the Tumour Marker Panel (CEA, AFP, CA 19-9, CA 125, CA 15-3) worth doing in Singapore?
Judged for screening an asymptomatic adult, Tumour Marker Panel (CEA, AFP, CA 19-9, CA 125, CA 15-3) grades weak on our rubric. It typically costs S$150–400 in Singapore. It is most appropriate for not asymptomatic adults. Appropriate for monitoring a known, diagnosed cancer under specialist care. It is not recommended as a screen.
Weighing this against something else? Compare it with two other tests → · Price it inside a panel →